前列腺癌的ADT治疗前后代谢水平的差异对照研究  

Comparison of metabolic markers in prostate cancer patients before and after androgen deprivation therapy

作　　者：麦伍拉尼·马木提 艾则孜·麦麦提 艾克拜尔·吾曼尔[3] 袁杰 阿孜古力·克热木[4] 麦麦提艾力·艾则孜 彭光宪 黄发明 Maiwulani Mamuti;Aizezi Maimaiti;Aikebaier Wumaner;YUAN Jie;Aziguli Keremu;Maimaitiaili Aizezi;PENG Guangxian;HUANG Faming(Department of Urology,Seventh Affiliated Hospital of Xinjiang Medical University,Urumqi,830028,China;Department of General Surgery,Seventh Affiliated Hospital of Xinjiang Medical University;Department of Urology Center,People's Hospital of Xinjiang Uygur Autonomous Region;Department of Clinical Laboratory Center,People's Hospital of Xinjiang Uygur Autonomous Region)

机构地区：[1]新疆医科大学第七附属医院泌尿外科,乌鲁木齐830028 [2]新疆医科大学第七附属医院普通外科 [3]新疆维吾尔自治区人民医院泌尿中心 [4]新疆维吾尔自治区人民医院临床检验中心

出　　处：《临床泌尿外科杂志》2024年第7期582-588,共7页Journal of Clinical Urology

摘　　要：目的:探讨雄激素剥夺治疗(androgen deprivation therapy,ADT)前列腺癌中代谢水平的差异对照研究。方法:回顾性分析新疆维吾尔自治区人民医院泌尿中心和新疆医科大学第七附属医院泌尿外科2010年1月—2020年12月收治的342例前列腺癌患者的临床资料。均行ADT治疗,并且对前列腺癌患者治疗前及治疗后5年内的前列腺特异性抗原(PSA)、血糖、血脂[总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)、游离脂肪酸(Lp)]、乳酸脱氢酶(LDH)、碱性磷酸酶(ALP)、血红蛋白(HGB)、体重指数(BMI)变化水平进行对照研究。结果:本研究纳入了342例前列腺癌患者都完成随访5年,治疗前中位PSA水平为47.72(17.93,100.00)ng/mL,治疗后1个月开始PSA水平有下降趋势,与治疗前比较差异有统计学意义(P<0.05);治疗后1个月内血糖、ALP水平无明显变化,从第3个月开始有增高趋势,与治疗前比较差异有统计学意义(P<0.05);TC、TG、LDL-C、Lp、LDH、BMI水平从第1个月开始有增高趋势,与治疗前比较差异有统计学意义(P<0.05);HDL-C、HGB水平从第1个月开始有下降趋势,与治疗前比较差异有统计学意义(P<0.05)。结论:虽然ADT的使用有效降低了前列腺癌患者的PSA水平,但由此产生的性腺功能减退可引起血糖、ALP、LDH、BMI水平升高、血脂异常、HGB水平降低等代谢异常。Objective To investigate the difference of metabolic levels in androgen deprivation therapy(ADT)for the treatment of prostate cancer.Methods The clinical data of 342 patients with prostate cancer admitted to Urology Center of People's Hospital of Xinjiang Uygur Autonomous Region and Department of Urology of Seventh Affiliated Hospital of Xinjiang Medical University from January 2010 to December 2020 were retrospectively analyzed.ADT was performed in all patients with prostate cancer,and the changes of PSA,blood glucose,blood lipids(TC,TG,HDL-C,LDL-C,Lp),LDH,ALP,HGB and BMI were studied before and 5 years after treatment.Results The median PSA level before treatment was 47.72 ng/mL(range:17.93-100.00 ng/mL),and it began to decrease 1 month after the treatment.Blood glucose and ALP levels did not change significantly within 1 month of treatment,but there was an increase starting at 3 months,showing statistically significant difference from the level before treatment(P<0.05).TC,TG,LDL-C,Lp,LDH,and BMI increased starting at 1 month.HDL-C and HGB began decreasing at 1 month.The differences in the values for all these metabolic markers before and after treatment were statistically significant(P<0.05).Conclusion Although ADT effectively reduced PSA level in patients with prostate cancer,the resulting hypogonadism can cause metabolic abnormalities,such as elevated blood glucose,ALP,LDH,and BMI levels,dyslipidemia,and decreased HGB level.These levels should be monitored to ensure appropriate early intervention.

关 键 词：前列腺癌 雄激素剥夺治疗 代谢异常 

分 类 号：R737.25[医药卫生—肿瘤]